Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake
The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.
Abstract
Obesity is a growing epidemic, and current medical therapies have proven inadequate. Endogenous satiety hormones provide an attractive target for the development of drugs that aim to cause effective weight loss with minimal side effects. Both glucagon and GLP-1 reduce appetite and cause weight loss. Additionally, glucagon increases energy expenditure. We hypothesized that the combination of both peptides, administered at doses that are individually subanorectic, would reduce appetite, while GLP-1 would protect against the hyperglycemic effect of glucagon. In this double-blind crossover study, subanorectic doses of each peptide alone, both peptides in combination, or placebo was infused into 13 human volunteers for 120 min. An ad libitum meal was provided after 90 min, and calorie intake determined. Resting energy expenditure was measured by indirect calorimetry at baseline and during infusion. Glucagon or GLP-1, given individually at subanorectic doses, did not significantly reduce food intake. Coinfusion at the same doses led to a significant reduction in food intake of 13%. Furthermore, the addition of GLP-1 protected against glucagon-induced hyperglycemia, and an increase in energy expenditure of 53 kcal/day was seen on coinfusion. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
In the citing paper
“In human proof-of-concept studies, co-administration of GLP-1 and glucagon revealed benefits over GLP-1 receptor agonists alone, including further reduction in food intake, increased energy expenditure, increased hepatic fatty acid oxidation, reduced hepatic lipid accumulation, and improved mitochondrial function, without compromising glycaemic control.145”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [145]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Obesity : Preventing and managing the global epidemic
Akram, D. S., Astrup, A. V., Atinmo, T., Boissin, J.-L., Bray, G. A., Carroll, K. N., Chitson, P., Chen, C., Dietz, W. H., Hill, J. O., et al. (2000) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 12,945
New methods for calculating metabolic rate with special reference to protein metabolism
Weir, J. B. D. V. (1949) · The Journal of Physiology · doi:10.1113/jphysiol.1949.sp004363 · Cited by 5,603 · cited 1×
“Resting energy expenditure (REE), respiratory quotient (RQ), and carbohydrate and fat oxidation rates were calculated from the VO2 and VCO2 measured at 1-min intervals, and adjusted for urinary nitrogen excretion (27,28).”
MethodThe thrifty phenotype hypothesis
Hales, C. N., & Barker, D. J. P. (2001) · British Medical Bulletin · doi:10.1093/bmb/60.1.5 · Cited by 2,738 · cited 1×
“The current study was therefore designed to demonstrate the acute effects of intravenous infusion of GLP-1 and glucagon when given at low doses, both alone and in combination, on food intake (22), glucose homeostasis, and energy expenditure in humans.”
BackgroundCalculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365 · cited 1×
“Resting energy expenditure (REE), respiratory quotient (RQ), and carbohydrate and fat oxidation rates were calculated from the VO2 and VCO2 measured at 1-min intervals, and adjusted for urinary nitrogen excretion (27,28).”
MethodChanges in Energy Expenditure Resulting from Altered Body Weight
Leibel, R. L., Rosenbaum, M., & Hirsch, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321001 · Cited by 2,012 · cited 1×
“Appetite inhibition classically results in defense of body weight by a reduction of energy expenditure (7,8).”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 3×
“GLP-1’s insulinotropic effects are dependent on the prevailing glucose level (10), which accounts for the relatively small insulinotropic response observed during GLP-1 infusion alone, as glucose levels tend to decline after the start of the infusion (Fig.”
BackgroundMethodSelf-citationThe SCOFF questionnaire: Assessment of a new screening tool for eating disorders
Morgan, J. F., Reid, F., & Lacey, J. H. (1999) · BMJ · doi:10.1136/bmj.319.7223.1467 · Cited by 1,416 · cited 1×
“Any abnormal eating behavior was assessed using the Dutch Eating Behavior Questionnaire (23) and the SCOFF questionnaire (24).”
MethodGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“The postprandial nausea seen in this study may instead be accounted for by a delay in gastric emptying triggered by glucagon and GLP-1 (31,32).”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“As a result, GLP-1 is capable of achieving a modest reduction in body weight (12).”
Background
Cited by
Items 101–161 of 161
Liu, J., Liu, S., Gurung, R. L., Chan, C., Ang, K., Tang, W. E., Subramaniam, T., Sum, C. F., & Lim, S. C. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00321 · Cited by 21
Stahel, P., Lee, S. J., Sud, S. K., Floh, A., & Dash, S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13661 · Cited by 18
Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges
Huang, X., Liu, J., Peng, G., Lu, M., Zhou, Z., Jiang, N., & Yan, Z. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0404 · Cited by 20
Kaplan, L. M., Startseva, E., le Roux, C. W., Wharton, S., Bozkurt, B., Mazo, D. F. D. C., von Schlippenbach, J., Maldonado, S. G., Hussain, S. A., Neff, G. W., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04479-3 · Cited by 29
Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes
Ye, G., Ly, N. S., Li, J., & Arends, R. H. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01094-y · Cited by 16
Hope, D. C. D., & Tan, T. M.-M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170962 · Cited by 16
Self-citationPoly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“Human co-infusion studies have confirmed the promise of the combined effects of GLP-1 and glucagon on both energy balance and glucose homeostasis [126, 143].”
GLP-1 Based Combination Therapy for Obesity and Diabetes
Lee, Y. H., Lee, H. W., & Choi, H. J. (2017) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2017.26.3.155 · Cited by 12
Chen, T., Sun, T., Bian, Y., Pei, Y., Feng, F., Chi, H., Li, Y., Tang, X., Sang, S., Du, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01456 · Cited by 11
Glucagon-based therapy for people with diabetes and obesity: What is the sweet spot?
McGlone, E. R., & Tan, T. (2024) · Peptides · doi:10.1016/j.peptides.2024.171219 · Cited by 11
“This approach has been underpinned by studies in which glucagon and GLP-1 have been co-infused, resulting in an increase in energy expenditure when compared to GLP-1 infusion alone and attenuation of hyperglycemia when compared to glucagon alone [51,52].”
ResultSelf-citationNovel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
Rose, F., Bloom, S. R., & Tan, T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1646243 · Cited by 11
Self-citationFrom Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Cabré, F., Centelles, J. J., & Cascante, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091125 · Cited by 16
“In fact, some studies demonstrated that the simultaneous infusion of GLP-1 at low doses and glucagon can suppress appetite and boost energy expenditure, as was observed when each peptide was administered individually [125].”
Glucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
Increased food intake with oxyntomodulin analogues
Price, S. L., MINNION, J. S., & Bloom, S. R. (2015) · Peptides · doi:10.1016/j.peptides.2015.09.006 · Cited by 11
Self-citationGlucagon receptor signalling – backwards and forwards
Wu, T., Rayner, C. K., Marathe, C. S., Jones, K. L., & Horowitz, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1428306 · Cited by 10
Neff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“71,72 Furthermore, in one study, co-infusion of sub-anorectic doses of glucagon and GLP-1 reduced food intake in overweight individuals without diabetes, even though no significant anorectic effect was observed when each hormone was given alone at the same dose.”
Guo, H., Sui, C., Ge, S., Cai, J. Q., Lin, D., Guo, Y., Wang, N., Zhou, Y., Ying, R., Zha, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3550 · Cited by 8
Hamasaki, H., & Morimitsu, S. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.108 · Cited by 10
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes
Elmendorf, A. J., Yousefian, M., Kim, I., Hardaway, J. A., Habegger, K. M., & Flak, J. N. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108077 · Cited by 8
“The combination of GLP-1 and GCG receptor agonism has a synergistic effect on reducing food intake in humans, which allows for a reduced dose of GLP-1R agonist [62].”
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Hope, D. C. D., Ansari, S., Choudhury, S., Αλεξιάδου, Κ., Tabbakh, Y., Ilesanmi, I., Lazarus, K., Davies, I., Jimenez‐Pacheco, L., Yang, W. P., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15448 · Cited by 6
“9,10 Subsequently, several GCGR-targeted multi-agonists have progressed to early phase clinical trials and have shown promising initial results, including the GLP-1R/ GCGR co-agonists LY3305677, 11 cotadutide 12 and BI 456906.”
BackgroundSelf-citationShpakov, A. O., & Derkach, K. V. (2017) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-017-0426-y · Cited by 6
Pacini, G., & Åhrén, B. (2015) · Peptides · doi:10.1016/j.peptides.2015.05.010 · Cited by 7
Innovative Glucagon-based Therapies for Obesity
Belay, K. E., Jemal, R. H., & Tuyizere, A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae197 · Cited by 8
Literature Review on Obesity: Causes, Treatment and Correlation with Pandemic COVID-19
Sebaiy, M. M. (2021) · Pharmaceutical Drug Regulatory Affairs Journal · doi:10.23880/pdraj-16000124 · Cited by 5
Kanu, C., Boye, K. S., Poon, J. L., GOETZ, I. A., WILLIAMSON, S. E., Lou, J., Hartman, M. L., Martin, C. K., & Coşkun, T. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70097 · Cited by 6
“Appetite VAS results were collected in a fasting state in the morning at baseline and Weeks 4, 8, 12, 16, 24, and 36, and consisted of eight questions, each scored on a straight line from 0 to 100 (Supplementary Table 1).”
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Zhang, X., Cai, Y., Yao, Z., Chi, H., Li, Y., Shi, J., Zhou, Z., & Sun, L. (2023) · Peptides · doi:10.1016/j.peptides.2023.170948 · Cited by 6
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Izzi‐Engbeaya, C. N., Salem, V., Atkar, R. S., Coello, C. S., Thomas, D., Comninos, A. N., Buckley, A. J., Rabiner, E. A., Gunn, R. N., Tan, T., et al. (2015) · Endocrine Abstracts · doi:10.1530/endoabs.38.oc4.5 · Cited by 4
Self-citationGoodman, J., Schain, M., Stefano, G. D., Lupson, V. C., Horn, T., Hill, M., Manavaki, R., Fryer, T. D., Bumanlag-Amis, E., Jalaludeen, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04559-3 · Cited by 5
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
“Co-administration of GLP-1 and glucagon is more effective than GLP-1 alone at reducing food intake, increasing energy expenditure and hepatic fatty acid oxidation and decreasing hepatic lipid content [44].”
Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus
Koch, T. R., Shope, T. R., & Camilleri, M. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i11.180 · Cited by 4
Advances in clinical research on glucagon
Horie, I., & Abiru, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00705-w · Cited by 3
“Gluca-gon agonism combined with an incretin enhancer was shown to have synergistic effects on the increase in insulin secretion and a decrease in appetite [88] in addition to an increase in energy expenditure as its own specific effect [89].”
Lopes, T., Hope, D. C. D., Pittol, J. M. R., Curtis, A., Shrewsbury, J. V., Davies, I., Zhou, Z., Sardini, A., MINNION, J. S., Dormann, D., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102024 · Cited by 3
“Somewhat counterintui-tively, chronic glucagon receptor agonism also improves glycemia [6 e 9].”
BackgroundSelf-citationMEYTS, P. D., & Lefèbvre, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00017-1 · Cited by 4
Hopkins, M., Andrews, R. C., Salem, V., Taylor, R., le Roux, C. W., Robertson, E., & Burns, E. (2020) · Diabetic Medicine · doi:10.1111/dme.14358 · Cited by 4
Polypharmacology in Clinical Applications: Metabolic Disease Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_5 · Cited by 3
Zimmermann, T., Bleymehl, K., Haebel, P., Perens, J., Roostalu, U., Hecksher‐Sørensen, J., Doerr, J., Jarosch, S., Lam, D. D., Klein, H., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102326 · Cited by 5
Xiang, B., Sun, Q., He, M., Wu, W., Lü, B., Zhang, S., Zhang, Z., Yang, Y., Li, Y., Wu, Y., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.693669 · Cited by 2
Alvos moleculares dos fármacos utilizados na perda de peso dos pacientes com obesidade
Santana, G. S., dos Reis, M. R., Santos, M. D. S., Costa, L. Q. S., de Franca, M. N. F., de Almeida, G. K. M., Seabra, M. S. D. M., & Souza, M. T. D. S. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n1-067 · Cited by 3
Insulin, Other Hypoglycemic Drugs, and Glucagon
Escaño, A. K. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.05.006 · Cited by 3
Abbas, E., Siddiqui, I. A., Khan, M. S., Perveen, K., Butt, A., & Fawwad, A. (2021) · Cureus · doi:10.7759/cureus.13430 · Cited by 3
“[27] reported that glucagon infusion increased the respiratory exchange ratio, resting energy expenditure rate, and carbohydrate and fat oxidation rates in healthy individuals.”
BackgroundGlucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Goodman, J., Parker, V., McEniery, C. M., Stefano, G. D., Hubsch, A., Vamvaka, E., Helmy, J., Kaloyirou, F., Jalaludeen, N., Barker, P. J., et al. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70282 · Cited by 2
MASLD as Complication of Diabetes
Stefan, N. (2026) · Diabetes · doi:10.2337/dbi26-0001 · Cited by 4
Lower glucagon response and attenuated hepatic glucagon signaling in MASLD
Kim, S. R., Hwang, Y., Lee, M., Choi, A., Lee, B., Kang, E. S., Cha, B., Kim, K. J., & Lee, Y. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101787 · Cited by 1
Glucagon-Like Peptide 1 and Human Obesity
Anandhakrishnan, A., & Korbonits, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48559-3.00003-8 · Cited by 1
Glucagon receptor modulation: Its role in diabetes care
Seshadri, K., Sosale, A., Kumar, K. M. P., Reddy, S. C., & CHAWLA, P. M. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_106_23 · Cited by 1
Inkretinbasierte Medikamente zur Diabetes- und Adipositastherapie
Götz, A., Jall, S., Tschöp, M., & Müller, T. D. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0267-x · Cited by 1
Obesity and Current Treatment Approaches: A Comprehensive Review
Mathialagan, K., Madhumitha, R., Muralidharan, K., & Jang, S.-J. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00040 · Cited by 1
Nicol, A., Ahmed, M., Fischer, C., Garces, J. G., Magnus, S., Maung, N., Molisani, N., Petrov, S., & Palu, R. A. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302565
Anti-Obesity Agents on the Horizon
Kim, S. H. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.1.2
Winther‐Sørensen, M., Rasmussen, C. B., Trammell, S. A. J., Hansen, C., Vyberg, M., Serizawa, R., Richter, E. A., Grevengoed, T. J., Gluud, L. L., Kuhre, R. E., et al. (2025) · Peptides · doi:10.1016/j.peptides.2025.171462 · Cited by 2
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
“However, discontinuation rates exceeded 50% due to gastrointestinal adverse events (AEs) [243].”
Duale und triagonistische Inkretine: Stand und Einfluss auf die MASLD
Kirchhoff, M., & Schattenberg, J. M. (2026) · Die Gastroenterologie · doi:10.1007/s11377-026-01015-0
BindingDB (2020) · UC San Diego · doi:10.7270/q2fn18tn
Metadata
- Authors
- Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., Minnion, J., Cuenco, J., Ghatei, M. A., Meeran, K., Tan, T. M., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Bloom, Stephen R.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-13
- Volume
- 63
- Issue
- 11
- Pages
- 3711-3720
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2115939390
- Cited by
- 159
- References
- 49
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 19 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 12 · 2018: 16 · 2017: 11 · 2016: 9 · 2015: 17 · 2014: 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (ACF-2007-21-023, ACF-2010-21-012, ACF-2010-21-017)
- Imperial College Healthcare NHS Trust
- National Institutes of Health
- Medical Research Council (MR/J010936/1, MR/K02115X/1, MR/K023667/1, MR/J010731/1)
- Biotechnology and Biological Sciences Research Council
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- glucagon-like peptide-1, glucagon, dietary intake, appetite, obesity, weight loss, satiety hormones, energy expenditure, hyperglycemia, diabetes treatment
- MeSH terms
- Adult, Eating, Glucagon, Humans, Hyperglycemia, Male, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.